New hope for muscle disease: experimental drug ARO-DM1 enters human trials

NCT ID NCT06138743

First seen Nov 11, 2025 · Last updated May 10, 2026 · Updated 17 times

Summary

This study tests an experimental drug called ARO-DM1 in 78 adults with type 1 myotonic dystrophy, a genetic muscle disorder. The main goal is to see if the drug is safe and how it moves through the body. Participants receive either the drug or a placebo, and the study is still recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Liverpool, New South Wales, 2170, Australia

  • Research Site

    RECRUITING

    Birtinya, Queensland, 4575, Australia

  • Research Site

    RECRUITING

    Herston, Queensland, 4029, Australia

  • Research Site

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Research Site

    RECRUITING

    Christchurch, 8011, New Zealand

  • Research Site

    RECRUITING

    Taichung, 40447, Taiwan

  • Research Site

    RECRUITING

    Taipei, 10041, Taiwan

  • Research Site

    RECRUITING

    Taipei, 11217, Taiwan

  • Research Site

    RECRUITING

    Bangkok, Bangkok, 10700, Thailand

  • Research Site

    RECRUITING

    Hat Yai, Changwat Songkhla, 90110, Thailand

  • Research Site

    RECRUITING

    Lampang, 52000, Thailand

Conditions

Explore the condition pages connected to this study.